Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advaxis, Incorporated
Advaxis Prevails in European Patent Court
January 28th, 2009
The European Patent Court in Munich, Germany has ruled in favor of Advaxis Incorporated (OTCBB: ADXS) and reversed a patent challenge made by Anza Therapeutics, Inc., formerly Cerus Corp (NASDAQ: CERS). The Court’s ruling is final and can not be appealed. The challenge was made against elements of a patent filed, and subsequently published in 1994, by Dr. Yvonne Paterson, scientific founder of Advaxis. The patent describes the use of bacteria to deliver an antigen and generate an anti-tumor immune response. Executive VP of Science and Operations Dr. John Rothman commented, "Following the completion of Advaxis’ Phase I clinical trial in recurrent...
Source: Vaccine Weekly (2009-01-28)
|
